« Recruiting Patients for Clinical Trials on the Internet | Main | Cymbalta Gets FDA Approval as Maintenance Treatment of Major Depressive Disorder »

Nov30
Thomson Scientific Issues List of Most Promising Drugs in Development

Thomson Scientific has issued its quarterly "The Ones to Watch" report which lists the five most promising drugs in the pharmaceutical pipeline.

Most Promising Drugs from July - September 2007

  1. Exelon TDS - a transdermal patch of rivastigmine from Novartis. Indicated for the use with patients suffering from Alzheimer's disease and Parkinson's related dementia. The oral formulation was FDA approved in 2000 and approval for mile to moderate dementia in July 2007.
  2. AZOR - for the treatment of hypertension from Daiichi Sankyo. A combination drug that achieved greater reduction in blood pressure than either drug alone, FDA approval was granted in September 2007.
  3. EvaMist - indicated for use by women experiencing menopause. A small, easy to use, hand held applicator that delivers a pre-set metered dose of estradoil into the bloodstream over 24 hours. EvaMist received FDA approval in July 2007.
  4. Yondelis - developed by PharmaMar for patients that have not reposonded to previous regimes in the treatment of soft tissue sarcoma
  5. Tasigna - an orally available inhibitor of Bcr-Abl, c-Kit, PDGF-R and related receptor tyrosine kinases for the potential treatment of various types of leukemia from Novartis. Approved in Switzerland, it is waiting on FDA approval.

From the report here are the top drugs in each phase of clinical trials:


    The Five Most Promising Drugs Entering Phase III Trials
    -- bevasiranib sodium, (Wet AMD), Opko
    -- recombinant active glucocerebrosidase, (Gaucher's disease), Protalix
    -- odanacatib, (osteoporosis), Merck & Co
    -- laquinimod, (multiple sclerosis), Active Biotech/Teva
    -- elesclomol, (solid tumors), Synta

    The Five Most Promising Drugs Entering Phase II Trials
    -- CPP-109, (addiction to cocaine and methamphetamine), Catalyst
       Pharmaceuticals
    -- intranasal insulin formulation, (diabetes), Nastech
    -- LCP-AtorFen, (cholesterol), Life Cycle
    -- EC-145, (ovarian and lung cancer), Endocyte
    -- TG-100801, (AMD, diabetic macular edemia, diabetic retinopathy),
       TargeGen

    The Five Most Promising Drugs Entering Phase I Trials
    -- affitope AD-01, (Alzheimer's disease), AFFiRiS
    -- MEM-63908, (Alzheimer's disease, CNS disorders), Memory/Roche
    -- TC-5619, (schizophrenia, depression), Targacept
    -- RDEA-806, (HIV infection), Ardea Biosciences
    -- APD-791, (arterial thrombosis), Arena Pharmaceuticals

[Source: PRNews]


1 Comments/Trackbacks




» Merck & Co. from PharmaGazette
U.S. based Merck & Co. (NYSE:MRK) was 8th in total sales and #7 ($3.62 bn EUR)in R&D spending in 2006. Merck has had success with the U.K mandating HPV for all school age girls and its vaccine, Gardasil, is in the... [Read More]

submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Recruiting Patients for Clinical Trials on the Internet | Main | Cymbalta Gets FDA Approval as Maintenance Treatment of Major Depressive Disorder »

Advertise

Watch the Digital Health Revolution


sponsored ads



subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

BrainBasedBusiness

TheInsurancePolicy

MarketingBlurb